Fosinopril (Monograph)
Drug class: Angiotensin-Converting Enzyme Inhibitors
- ACE Inhibitors
VA class: CV800
Molecular formula: C30H46NO7P
CAS number: 88889-14-9
Warning
Introduction
Nonsulfhydryl ACE inhibitor.1 2 3
Uses for Fosinopril
Hypertension
Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 3 1200
ACE inhibitors are recommended as one of several preferred agents for the initial management of hypertension according to current evidence-based hypertension guidelines; other preferred options include angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics.501 502 503 504 1200 While there may be individual differences with respect to recommendations for initial drug selection and use in specific patient populations, current evidence indicates that these antihypertensive drug classes all generally produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.501 502 504 1200
Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201
A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)
Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.
Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).
Category |
SBP (mm Hg) |
DBP (mm Hg) |
|
---|---|---|---|
Normal |
<120 |
and |
<80 |
Elevated |
120–129 |
and |
<80 |
Hypertension, Stage 1 |
130–139 |
or |
80–89 |
Hypertension, Stage 2 |
≥140 |
or |
≥90 |
The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229
The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) of < 130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210
Other hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients501 504 536 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200
Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229
Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.1200 1220
For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.1200
ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200
For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200
Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200
In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200
Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to ACE inhibitors.44 45 60 61 501 504 1200 However, the combination of an ACE inhibitor or an angiotensin II receptor antagonist with a calcium-channel blocker or thiazide diuretic produces similar BP lowering in black patients as in other racial groups.1200
ACE inhibitors may be preferred in hypertensive patients with heart failure, ischemic heart disease, diabetes mellitus, CKD, or cerebrovascular disease or post-MI.501 502 504 523 524 525 526 527 534 535 536 543 1200 1214 1215
Heart Failure
Management of heart failure, usually in conjunction with other agents such as cardiac glycosides, diuretics, and β-adrenergic blocking agents (β-blockers).1 15 524 800
Some evidence indicates that therapy with an ACE inhibitor (enalapril) may be less effective than angiotensin receptor-neprilysin inhibitor (ARNI) therapy (e.g., sacubitril/valsartan) in reducing cardiovascular death and heart failure-related hospitalization.702 800
ACCF, AHA, and the Heart Failure Society of America (HFSA) recommend that patients with chronic symptomatic heart failure and reduced left ventricular ejection fraction (LVEF) (NYHA class II or III) who are able to tolerate an ACE inhibitor or angiotensin II receptor antagonist be switched to therapy containing an ARNI to further reduce morbidity and mortality.800
Diabetic Nephropathy
A recommended agent in the management of patients with diabetes mellitus and persistent albuminuria† [off-label] who have modestly elevated (30–300 mg/24 hours) or higher (>300 mg/24 hours) levels of urinary albumin excretion; slows rate of progression of renal disease in such patients.53 54 55 56 57 535 536 1232
Fosinopril Dosage and Administration
General
BP Monitoring and Treatment Goals
-
Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.1200
-
If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.1216
-
If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., calcium-channel blocker, thiazide diuretic).1200 1216 Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.1200 1216 1220
Administration
Oral Administration
Administer orally once daily.1 Manufacturer makes no specific recommendations regarding administration with meals.1 43
Dosage
Available as fosinopril sodium; dosage expressed in terms of the salt.1
May minimize risk of hypotension in patients currently receiving diuretic therapy by discontinuing the diuretic, reducing diuretic dosage, or increasing salt intake prior to initiating fosinopril; if these changes are not possible, reduce initial fosinopril sodium dosage and observe patient closely for several hours until BP has stabilized.600 (See Hypotension under Cautions and see the individual dosage sections in Dosage and Administration.)
Pediatric Patients
Hypertension
Oral
Children ≥6 years of age and weighing <50 kg: Initial dosage of 0.1 mg/kg (up to 5 mg) daily recommended by some experts;1150 however, a dosage form suitable for providing an appropriate dosage for children weighing <50 kg is not commercially available in the US.1 Safety and efficacy of dosages >40 mg daily not established.1150
Children ≥6 years of age and weighing >50 kg: 5–10 mg once daily.1 1150 Some experts state that the drug should be initiated at the low end of the dosage range; dosage should be increased every 2–4 weeks until BP controlled, maximum dosage reached, or adverse effects occur.1150 Safety and efficacy of dosages >40 mg daily not established.1150
Adults
Hypertension
Fosinopril Therapy
OralInitially, 10 mg once daily in patients not receiving a diuretic.600 Adjust dosage based on BP response.600
In patients currently receiving diuretic therapy, discontinue diuretic, if possible, 2–3 days before initiating fosinopril.3 600 May resume diuretic therapy if BP not controlled adequately with fosinopril alone.600 If usual initial dosage of 10 mg daily is used in patients receiving a diuretic, administer under close medical supervision for several hours until BP has stabilized.600
Usual maintenance dosage: Manufacturer states 20–40 mg daily.600 Some experts state 10–40 mg once daily.1200 Higher dosages (e.g., 80 mg daily) reportedly have resulted in increased response in some patients.600
If effectiveness diminishes toward end of dosing interval in patients treated once daily, consider increasing dosage or administering drug in divided doses.600
Fosinopril/Hydrochlorothiazide Fixed-combination Therapy
OralManufacturer states fixed-combination preparation should not be used for initial antihypertensive therapy.43
If BP is not adequately controlled by monotherapy with fosinopril, can switch to the fixed-combination preparation containing fosinopril sodium 10 mg and hydrochlorothiazide 12.5 mg, or alternatively, fosinopril sodium 20 mg and hydrochlorothiazide 12.5 mg.43 43
On average, antihypertensive effect of fosinopril sodium 10 mg and hydrochlorothiazide 12.5 mg is similar to that of fosinopril sodium 40 mg or hydrochlorothiazide 37.5 mg as monotherapy.43
Heart Failure
Oral
Initially, 10 mg daily.1 524 If patient has been treated vigorously with diuretics, 5 mg initially.1 524 Monitor closely for ≥2 hours until BP has stabilized.1 To minimize risk of hypotension, reduce diuretic dosage, if possible.1
Adjust dosage gradually over several weeks to maximum tolerated dosage (up to 40 mg daily).1 524
Usual dosage: 20–40 mg once daily.1
Prescribing Limits
Pediatric Patients
Hypertension
Oral
Adults
Heart Failure
Oral
Maximum 40 mg daily.1
Special Populations
Hepatic Impairment
No specific dosage recommendations.1 (See Special Populations under Pharmacokinetics.)
Renal Impairment
Hypertension
Dosage adjustment not required.1
Fosinopril/hydrochlorothiazide fixed combinations are not recommended in patients with Clcr <30 mL/minute or Scr ≥3 mg/dL.601
Heart Failure
Initially, 5 mg in patients with moderate to severe renal impairment.1
Geriatric Patients
Select dosage carefully; monitoring renal function may be useful.1
Cautions for Fosinopril
Contraindications
-
Known hypersensitivity to fosinopril or any ingredient in the formulation or another ACE inhibitor.1
Warnings/Precautions
Warnings
Hypotension
Possible symptomatic hypotension, particularly in volume- and/or salt-depleted patients (e.g., those treated with diuretics or undergoing dialysis, patients with diarrhea or vomiting).1
Risk of marked hypotension, sometimes associated with oliguria, azotemia, and, rarely, death, in patients with heart failure with or without associated renal insufficiency.1
Hypotension may occur in patients undergoing surgery or during anesthesia with agents that produce hypotension; recommended treatment is fluid volume expansion.1
To minimize potential for hypotension, consider recent antihypertensive therapy, extent of BP elevation, sodium intake, fluid status, and other clinical conditions.1
May minimize potential for hypotension by correcting volume and/or salt depletion prior to initiating fosinopril therapy.1
Initiate therapy in patients with heart failure under close medical supervision; monitor closely for first 2 weeks following initiation of fosinopril or any increase in fosinopril or diuretic dosage.1 Consider reduced diuretic dosage in patients with low to normal BP who are hyponatremic or have received vigorous diuretic therapy.600
If excessive hypotension occurs, immediately place patient in supine position and, if necessary, administer IV infusion of 0.9% sodium chloride.1 Fosinopril therapy usually can be continued following restoration of volume and BP.1
Fetal/Neonatal Morbidity and Mortality
Possible fetal and neonatal morbidity and mortality when used during pregnancy.1 63 (See Boxed Warning.) Such potential risks occur throughout pregnancy, especially during the second and third trimesters.63
Also may increase the risk of major congenital malformations when administered during the first trimester of pregnancy.62 63
Discontinue as soon as possible when pregnancy is detected, unless continued use is considered lifesaving.63 Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.31 33
Hepatic Effects
Clinical syndrome that usually is manifested initially by cholestatic jaundice and may progress to fulminant hepatic necrosis (occasionally fatal) reported rarely with ACE inhibitors.1
If jaundice or marked elevation of liver enzymes occurs, discontinue drug and monitor patient.1
Hematologic Effects
Neutropenia and agranulocytosis reported with captopril; risk of neutropenia appears to depend principally on presence of renal impairment and presence of collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma); risk with fosinopril is unknown.1
Consider monitoring leukocytes in patients with collagen vascular disease, especially if renal impairment exists.1
Sensitivity Reactions
Anaphylactoid reactions and/or head and neck angioedema possible; angioedema involving tongue, glottis, or larynx may be fatal.1 If angioedema occurs, promptly discontinue perindopril and observe patient until swelling disappears.1 Immediate medical intervention (e.g., epinephrine) for involvement of tongue, glottis, or larynx.1
Intestinal angioedema possible; consider in differential diagnosis of patients who develop abdominal pain.1 43
Anaphylactoid reactions reported in patients receiving ACE inhibitors while undergoing LDL apheresis with dextran sulfate absorption or following initiation of hemodialysis that utilized high-flux membrane.1
Life-threatening anaphylactoid reactions reported in at least 2 patients receiving ACE inhibitors while undergoing desensitization treatment with hymenoptera venom.1
Contraindicated in patients with a history of angioedema associated with ACE inhibitors.1
General Precautions
Renal Effects
Transient increases in BUN and Scr possible, especially in patients with preexisting renal impairment or those receiving concomitant diuretic therapy.1 Possible increases in BUN and Scr in patients with unilateral or bilateral renal artery stenosis; generally reversible following discontinuance of ACE inhibitor and/or diuretic.1
Possible oliguria, progressive azotemia, and, rarely, acute renal failure and/or death in patients with severe heart failure.1
Closely monitor renal function for the first few weeks of therapy in hypertensive patients with unilateral or bilateral renal-artery stenosis.1 43 Some patients may require dosage reduction or discontinuance of ACE inhibitor or diuretic.1
Hyperkalemia
Possible hyperkalemia, especially in patients with renal impairment or diabetes mellitus and those receiving drugs that can increase serum potassium concentration (e.g., potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes).1
Monitor serum potassium concentration carefully in these patients.1
Cough
Persistent and nonproductive cough; resolves after drug discontinuance.1
Use of Fixed Combinations
When used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with hydrochlorothiazide.43
Specific Populations
Pregnancy
Category C (1st trimester); Category D (2nd and 3rd trimesters).1 (See Fetal/Neonatal Morbidity and Mortality under Cautions and see Boxed Warning.)
Lactation
Distributed into milk.1 Use not recommended.1
Pediatric Use
Safety and efficacy not established in children <6 years of age.1
Safety and efficacy of fosinopril in combination with hydrochlorothiazide not established in children.43
Geriatric Use
Insufficient experience in patients >65 years of age to determine whether geriatric patients respond differently than younger adults.1
Select dosage with caution because of greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy in the elderly.1
Hepatic Impairment
Systemic exposure to fosinoprilat may be increased (see Special Populations under Pharmacokinetics), but no specific dosage recommendations.1
Renal Impairment
Deterioration of renal function may occur.1 (See Renal Effects under Cautions.)
Dosage adjustment generally not required in patients with hypertension.1 Decrease initial dose in patients with heart failure and moderate to severe renal impairment.1 (See Renal Impairment under Dosage and Administration.)
Fosinopril/hydrochlorothiazide fixed combinations are not recommended in patients with Clcr <30 mL/minute or Scr ≥3 mg/dL.43
Black Patients
BP reduction may be smaller in black patients compared with patients of other races.44 45 (See Hypertension under Uses.)
Higher incidence of angioedema reported with ACE inhibitors in black patients compared with other races.1 45 1200
Common Adverse Effects
Patients with hypertension: Cough, dizziness, nausea/vomiting.1
Patients with heart failure: Dizziness, cough, hypotension, musculoskeletal pain, nausea/vomiting, diarrhea, chest pain (noncardiac).1
Drug Interactions
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Antacids (aluminum-, magnesium-, and simethicone-containing) |
Possible decreased fosinopril absorption1 |
Administer 2 hours apart1 |
Aspirin |
Effect on fosinopril bioavailability unlikely1 |
|
Cimetidine |
Effect on fosinopril bioavailability unlikely1 |
|
Digoxin |
Effect on fosinopril bioavailability unlikely1 |
|
Diuretics |
Increased hypotensive effect1 |
If possible, discontinue diuretic before initiating fosinopril1 (See Dosage under Dosage and Administration) |
Diuretics, potassium-sparing (amiloride, spironolactone, triamterene) |
Enhanced hyperkalemic effect1 |
Use with caution; monitor serum potassium concentration frequently1 |
Lithium |
Increased lithium concentrations; possible toxicity1 |
Use with caution, monitor lithium concentrations frequently1 |
Potassium supplements or potassium-containing salt substitutes |
Enhanced hyperkalemic effect1 |
Use with caution; monitor serum potassium concentrations frequently1 |
Propantheline |
Effect on fosinopril bioavailability unlikely1 |
|
Propranolol |
Effect on fosinopril bioavailability unlikely1 |
|
Warfarin |
Pharmacokinetic or pharmacologic interaction unlikely1 |
Fosinopril Pharmacokinetics
Absorption
Bioavailability
About 36% of oral dose is absorbed.1 Peak plasma concentration is achieved in approximately 3 hours.1
Onset
Following a single oral dose, antihypertensive effects are observed within 1 hour, with peak BP reductions at 2–6 hours.1
Duration
Antihypertensive effect of a single dose persists for about 24 hours.1
Food
Food may decrease rate but not extent of absorption.1 2
Distribution
Extent
Does not appear to cross blood-brain barrier.1
Crosses the placenta in animals.1 Distributed into human milk.1
Plasma Protein Binding
Fosinoprilat: About 99%.1
Elimination
Metabolism
Metabolized in the liver and gut wall, principally to an active metabolite (fosinoprilat).1
Elimination Route
Eliminated approximately equally by the liver and kidney.1
Not appreciably removed by hemodialysis or peritoneal dialysis.1
Half-life
Fosinoprilat: Approximately 12 hours.1
Special Populations
In patients with alcoholic or biliary cirrhosis, rate but not extent of metabolism of fosinopril may be decreased; clearance of fosinoprilat is approximately one-half that in patients with normal hepatic function.1
In patients with Clcr of 10–80 mL/minute, clearance of fosinoprilat is not appreciably altered.1 In patients with Clcr <10 mL/minute, clearance of fosinoprilat is approximately one-half that in patients with normal renal function.1
Stability
Storage
Oral
Tablets
15–30°C; protect from moisture.1 43
Actions
-
Prodrug; has little pharmacologic activity until hydrolyzed to fosinoprilat.1 2 3
-
Suppresses the renin-angiotensin-aldosterone system.1
Advice to Patients
-
Risk of angioedema, anaphylactoid reactions, or other sensitivity reactions.1 Importance of reporting sensitivity reactions (e.g., edema of face, eyes, lips, tongue, or extremities; hoarseness; swallowing or breathing with difficulty) immediately to clinician and of discontinuing the drug.1
-
Importance of reporting signs of infection (e.g., sore throat, fever).1
-
Risk of hypotension. Importance of informing clinicians promptly if lightheadedness or fainting occurs.1
-
Importance of adequate fluid intake; risk of volume depletion with excessive perspiration, dehydration, vomiting, or diarrhea.1 62 63
-
Risks of use during pregnancy.1 (See Boxed Warning.)
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs (including salt substitutes containing potassium).1
-
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.1
-
Importance of advising patients of other important precautionary information.1 (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets |
10 mg* |
Fosinopril Sodium Tablets |
|
20 mg* |
Fosinopril Sodium Tablets |
|||
40 mg* |
Fosinopril Sodium Tablets |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Tablets |
10 mg with Hydrochlorothiazide 12.5 mg* |
Fosinopril Sodium and Hydrochlorothiazide Tablets |
|
20 mg with Hydrochlorothiazide 12.5 mg* |
Fosinopril Sodium and Hydrochlorothiazide Tablets |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions March 4, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
1. Bristol-Myers Squibb. Monopril (fosinopril sodium) tablets prescribing information. Princeton, NJ; 2003 Jul.
2. Murdoch D, McTavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. Drugs. 1992; 43:123-40. http://www.ncbi.nlm.nih.gov/pubmed/1372856?dopt=AbstractPlus
3. McAreavey D, Robertson JIS. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs. 1990; 40:326-45. http://www.ncbi.nlm.nih.gov/pubmed/2226219?dopt=AbstractPlus
4. Bristol-Myers Squibb, Princeton, NJ: Personal communication.
5. Squibb. Capoten (captopril) tablets prescribing information. In: Physician’s desk reference. 47th ed. Montvale, NJ: Medical Economics Company Inc; 1993:2356-62.
6. Reviewers’s comments in enalapril/enalaprilat (personal observations).
8. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. http://www.ncbi.nlm.nih.gov/pubmed/6150424?dopt=AbstractPlus
10. US Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Med Bull. 1992; 22:2.
11. Sica DA, Cutler RE, Parmer RJ et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 1991; 20:420-7. http://www.ncbi.nlm.nih.gov/pubmed/1652404?dopt=AbstractPlus
13. Oster JR, Materson BL. Renal and electrolyte complications of congestive heart faiulure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med. 1992; 152:704-10. http://www.ncbi.nlm.nih.gov/pubmed/1558426?dopt=AbstractPlus
14. Leonetti G. Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs. 1995; 49:516-35. http://www.ncbi.nlm.nih.gov/pubmed/7789286?dopt=AbstractPlus
15. Brown EJ Jr, Chew PH, MacLean A et al for the Fosinopril Heart Failure Study Group. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis. Am J Cardiol. 1995; 75:596-600. http://www.ncbi.nlm.nih.gov/pubmed/7887385?dopt=AbstractPlus
16. Mason N. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990; 24:496-505. http://www.ncbi.nlm.nih.gov/pubmed/2188438?dopt=AbstractPlus
17. Baker DW, Konstam MA, Bottorff M. Management of heart failure. JAMA. 1994; 272:1361-6. http://www.ncbi.nlm.nih.gov/pubmed/7933398?dopt=AbstractPlus
18. Packer M, Lee WH, Yushak M. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986; 315:847-53. http://www.ncbi.nlm.nih.gov/pubmed/3018566?dopt=AbstractPlus
19. Zannad F, van den Broek SA, Bory M. Comparison of treatment with lisinopril versus enalapril for congestive heart failure. Am J Cardiol. 1992; 70:78-83C. http://www.ncbi.nlm.nih.gov/pubmed/1377441?dopt=AbstractPlus
20. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol. 1994; 43:151-63. http://www.ncbi.nlm.nih.gov/pubmed/8181869?dopt=AbstractPlus
21. Sharpe N. ACE inhibitors versus diuretics: when to choose which drug? Cardiovasc Drugs Ther. 1993; 7:877-9. Abstract.
22. Riegger GAJ. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1990; 15(Suppl 2): S41-6.
23. Erhardt L, Haunsol S, Luomanmaki K et al. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J. 1994; 15(Suppl):341.
24. Deedwania PC. Clinical profile of fosinopril, a novel phosphinic acid ACE inhibitor, for the treatment of heart failure. Heart Failure. 1995; 11:125-36.
25. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)
26. Rey E, LeLorier J, Burgess E et al. Report of the Canadian Hypertension Society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997; 157:1245-54. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1228354&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9361646?dopt=AbstractPlus
27. American College of Obstetricians and Gynecologists. ACOG technical bulletin No. 219: hypertension in pregnancy. 1996 Jan.
28. Hanssens M, Keirse MJ, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991; 78:128-35. http://www.ncbi.nlm.nih.gov/pubmed/2047053?dopt=AbstractPlus
29. Brent RL, Beckman D. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clincial teratology counselors. Teratology. 1991; 43:543-6. http://www.ncbi.nlm.nih.gov/pubmed/1882342?dopt=AbstractPlus
30. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992; 80:429-32. http://www.ncbi.nlm.nih.gov/pubmed/1495700?dopt=AbstractPlus
31. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med. 1996; 335:257-65. http://www.ncbi.nlm.nih.gov/pubmed/8657243?dopt=AbstractPlus
32. Barr M, Cohen MM. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology. 1991; 44:485-95. http://www.ncbi.nlm.nih.gov/pubmed/1771591?dopt=AbstractPlus
33. US Food and Drug Administration. Dangers of ACE inhibitors during pregnancy. FDA Med Bull. 1992; 22:2.
34. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.
35. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999; 100:2312-8. http://www.ncbi.nlm.nih.gov/pubmed/10587334?dopt=AbstractPlus
36. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341(10): 709-17. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4280563&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/10471456?dopt=AbstractPlus
37. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999;341:753-4.
38. Anon. Spironolactone for heart failure. Med Lett Drugs Ther. 1999; 41:81-2. http://www.ncbi.nlm.nih.gov/pubmed/10505071?dopt=AbstractPlus
39. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus
40. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus
41. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus
42. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site. http://www.diabetes.org/newsroom/
43. Bristol-Myers Squibb. Monopril-HCT (fosinopril sodium–hydrochlorothiazide) tablets prescribing information. 2003 May.
44. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus
45. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus
49. Novartis. Diovan (valsartan) tablets prescribing information. East Hanover, NJ; 2002 Aug.
53. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-62. http://www.ncbi.nlm.nih.gov/pubmed/8413456?dopt=AbstractPlus
54. Remuzzi G. Slowing the progression of diabetic nephropathy. N Engl J Med. 1993; 329:1496-7. http://www.ncbi.nlm.nih.gov/pubmed/8413463?dopt=AbstractPlus
55. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus
56. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-9. http://www.ncbi.nlm.nih.gov/pubmed/8295285?dopt=AbstractPlus
57. Fournier A. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1994; 330:937. http://www.ncbi.nlm.nih.gov/pubmed/8114873?dopt=AbstractPlus
60. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus
61. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus
62. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354:2443-51. http://www.ncbi.nlm.nih.gov/pubmed/16760444?dopt=AbstractPlus
63. Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053113.htm
64. Bristol-Myers Squibb, Plainsboro, NJ: Personal communication.
501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus
502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus
503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus
504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus
505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus
506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus
507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus
508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus
511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27. http://www.ncbi.nlm.nih.gov/pubmed/19139601?dopt=AbstractPlus
515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus
523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.
524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.
525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73. http://www.ncbi.nlm.nih.gov/pubmed/22052934?dopt=AbstractPlus
526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus
527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf
530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus
534. Qaseem A, Hopkins RH, Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159:835-47. http://www.ncbi.nlm.nih.gov/pubmed/24145991?dopt=AbstractPlus
535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3929429&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/23684145?dopt=AbstractPlus
536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.
541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701. http://www.ncbi.nlm.nih.gov/pubmed/22555213?dopt=AbstractPlus
543. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease (2002). From National Kidney Foundation website. http://www.kidney.org/professionals/kdoqi/guidelines_commentaries.cfm
600. Glenmark Generics. Fosinopril sodium tablets prescribing information. Mahwah, NJ; 2010 Apr.
601. Glenmark Generics. Fosinopril sodium and hydrochlorothiazide tablets prescribing information. Mahwah, NJ; 2013 Dec.
701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37:2129-200. http://www.ncbi.nlm.nih.gov/pubmed/27206819?dopt=AbstractPlus
702. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004. http://www.ncbi.nlm.nih.gov/pubmed/25176015?dopt=AbstractPlus
703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27. http://www.ncbi.nlm.nih.gov/pubmed/26992459?dopt=AbstractPlus
800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; 134:e282-93.
1150. Flynn JT, Kaelber DC, Baker-Smith CM et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017; 140 http://www.ncbi.nlm.nih.gov/pubmed/28827377?dopt=AbstractPlus
1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus
1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus
1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus
1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus
1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus
1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus
1213. Reboussin DM, Allen NB, Griswold ME et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71:2176-2198. http://www.ncbi.nlm.nih.gov/pubmed/29146534?dopt=AbstractPlus
1214. American Diabetes Association. 9. Cardiovascular disease and risk management: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41:S86-S104. http://www.ncbi.nlm.nih.gov/pubmed/29222380?dopt=AbstractPlus
1215. de Boer IH, Bangalore S, Benetos A et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017; 40:1273-1284. http://www.ncbi.nlm.nih.gov/pubmed/28830958?dopt=AbstractPlus
1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus
1218. Messerli FH, Bangalore S, Bavishi C et al. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?. J Am Coll Cardiol. 2018; 71:1474-1482. http://www.ncbi.nlm.nih.gov/pubmed/29598869?dopt=AbstractPlus
1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus
1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus
1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534?dopt=AbstractPlus
1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017
1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus
1232. American Diabetes Association. 10. Microvascular complications and foot care: standards of medical care in diabetes 2018. Diabetes Care. 2018; 41:S105-S118. http://www.ncbi.nlm.nih.gov/pubmed/29222381?dopt=AbstractPlus
Frequently asked questions
More about fosinopril
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: Angiotensin Converting Enzyme Inhibitors
- Breastfeeding
- En español